Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone
versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell
lung cancer.